Methods of improving the pharmacokinetics of migalastat
AssigneeAmicus Therapeutics, Inc.
InventorFranklin Johnson
Life of this patent
Estimating the term…
Abstract
Provided are methods of improving the pharmacokinetics of migalastat by limiting caffeine intake during migalastat therapy.
Claims20
A method of increasing migalastat bioavailability, the method comprising orally administering to a patient a formulation comprising a therapeutically effective dose of migalastat or a salt thereof, wherein the patient does not consume caffeine within about 2 hours of administering the formulation comprising migalastat or a salt thereof and wherein the patient consumes fruit juice without pulp within about 2 hours of administering the formulation comprising migalastat or a salt thereof.
A method of treatment of Fabry disease in a human patient in need thereof, the method comprising orally administering to the patient a formulation comprising a therapeutically effective dose of migalastat or a salt thereof, wherein the patient does not consume caffeine within 2 hours of administering the formulation comprising migalastat or a salt thereof and wherein the patient consumes fruit juice without pulp within about 2 hours of administering the formulation comprising migalastat or a salt thereof.
Dependencies are inferred from the claim text.